The oral triple monoamine reuptake inhibitor originally developed for Parkinson’s — now used off-label for aggressive fat loss, with Phase 2 data showing up to 12.8% body weight reduction.
Tesofensine is an oral small-molecule triple reuptake inhibitor — it blocks reuptake of dopamine, norepinephrine, and serotonin, raising levels of all three in the brain simultaneously. Unlike the other weight-loss compounds on this site, it is not a peptide and is taken by mouth.
Originally developed for Alzheimer’s and Parkinson’s, development shifted to obesity after Phase 2 trials showed dose-dependent weight loss up to 12.8% at 1 mg/day over 24 weeks — roughly double sibutramine’s effect.
Approved in Mexico (Tesomet) for obesity. Not FDA approved. Not WADA prohibited. Available internationally and as research chemical.
Blocks the reuptake transporters for dopamine (DAT), norepinephrine (NET), and serotonin (SERT). All three rise simultaneously — appetite falls, energy and focus rise.
Dopamine and norepinephrine in the hypothalamus reduce hunger; elevated serotonin adds satiety signaling. Cumulative effect is a strong appetite suppressant.
Increased sympathetic tone raises resting energy expenditure modestly — similar to ephedrine but milder.
| Benefit | Evidence |
|---|---|
| Weight loss | Astrup et al. (2008): 12.8% body-weight loss at 1 mg/day over 24 weeks; dose-dependent effect |
| Appetite suppression | Strong and sustained; reduces both hunger cravings and portion sizes |
| Focus & energy | Dopaminergic effect produces alertness and motivation; often described as similar to low-dose stimulant |
| Mood | Mild mood elevation (serotonin contribution); not an antidepressant, but a useful side effect |
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeThe pivotal Phase 2 trial (Astrup et al., PMID 18950853) used a 24-week continuous treatment period without a structured break protocol. The on/off cycling above is off-label convention, not a trial-validated dosing schedule.
Tesofensine is oral — typically supplied as 0.25 mg or 0.5 mg capsules. No reconstitution required.
Use our free peptide calculator to figure out your reconstitution volume, draw amount, and syringe units.
Open Peptide CalculatorDosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
Tesofensine’s monoamine effect means side effects are primarily cardiovascular and stimulating rather than GI.
Looking for Tesofensine? We recommend NextGen Peptides — third-party tested, fast shipping, and trusted by the StackTrax community.
10% off with code
Exclusive StackTrax discount
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeDisclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor. This page contains affiliate links — StackTrax may earn a commission on purchases at no extra cost to you.
© 2026 StackTrax, LLC. All rights reserved.
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.
These pages also contain affiliate links. We may earn a commission on purchases at no extra cost to you — this never changes our editorial recommendations.